论文部分内容阅读
三氧化二砷(Arsenic trioxide,As2O3)是中药砒霜的主要成分,有剧毒。既是一种致癌剂,又是一种广谱的抗癌药物。As2O3的抗肿瘤机制主要通过诱导肝癌细胞凋亡、选择性细胞毒作用及抗肿瘤血管形成等,不仅对白血病有效,而且对原发性肝、胆癌等实体肿瘤都有一定疗效。但其实验研究结果与临床疗效却存在着较大差距,如何通过与其他化疗药物的联合应用或多途径、多靶点导向治疗,达到减毒增效的目的,已成为当前研究的热点。
Arsenic trioxide (As2O3) is the main component of Chinese arsenic, highly toxic. Is both a carcinogen, but also a broad-spectrum anti-cancer drugs. As2O3 anti-tumor mechanism mainly through the induction of hepatocellular carcinoma cell apoptosis, selective cytotoxicity and anti-tumor angiogenesis, not only effective for leukemia, but also for the primary liver, gallbladder and other solid tumors have a certain effect. However, there is a big gap between experimental results and clinical efficacy. How to achieve the purpose of attenuating toxicity and enhancing efficacy through combination with other chemotherapeutic agents or multi-target and multi-target-directed therapy has become a hot spot in the current research.